Data Provided by Refinitiv. Minimum 15 minutes delayed.
–
Summary ToggleIntellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)
